Publisher
Springer Nature Singapore
Reference99 articles.
1. Akbari A, Ghahremani MH, Mobini GR, Abastabar M, Akhtari J, Bolhassani M et al (2015) Down-regulation of miR-135b in colon adenocarcinoma induced by a TGF-β receptor I kinase inhibitor (SD-208). Iran J Basic Med Sci 18(9):856
2. Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12(1):1–13
3. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK et al (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561
4. Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C et al (2019) Epstein− Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 33(1):132–147
5. Azoury SC, Straughan DM, Shukla V (2015) Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets 15(6):452–462